GPD 1116

Drug Profile

GPD 1116

Alternative Names: GPD-1116

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASKA Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Naphthyridines
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 23 Jun 2015 No recent reports on development identified - Phase-I for Allergic asthma in Germany (PO)
  • 23 Jun 2015 No recent reports on development identified - Phase-II for Allergic asthma in United Kingdom (PO)
  • 23 Jun 2015 No recent reports on development identified - Preclinical for Chronic obstructive pulmonary disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top